October 24, 2020

The Niche

Knoepfler lab stem cell blog

Month: February 2016

2 min read

Clinical research on Type I Diabetes is one of the most exciting and promising areas of stem cells and regenerative medicine for human disease. Two of the coolest companies out there in this arena have been ViaCyte and BetaLogics (owned by J&J). For more on ViaCyte see my interview with President and CEO Paul Laikind from 2015. Today brings great news for ViaCyte on two fronts. Incidentally, this gives me a correct prediction on my Top 20 stem cell predictions for 2016. First, it has …Read More

5 min read

A new report from the National Academies of Sciences (NAS), Engineering, and Medicine here in the US recommends a policy significantly more cautious on first read for 3-person IVF than that in place now in the UK. My initial take on this new 164-page report is that it is very well thought out and the recommendations are both appropriate and prudent. I’m still reading the report so it is possible I may feel differently at the end or that others may point out concerns …Read More

1 min read

California stem cell biotech, StemCells, Inc. ($STEM), has really struggled for years and its stock is now flatlining raising the question: can it cheat death? Will 2016 be the year that STEM turns things around? So far this year hasn’t started off that well. You can see the graph at right from today on the STEM stock price. Ron Leuty over at San Francisco Business Times reported a couple of weeks ago on a juicy severance package for departing STEM CEO Marty McGlynn despite …Read More

3 min read

With the approval today of the use of CRISPR in human embryos, the UK continues its recent trend toward a more permissive regulatory policy on human genetic modification. There are both risks and scientific benefits that come along with this trend. Last year the UK approved an experimental technology with the goal of preventing the transmission of mitochondrial disease. The approach would try to prevent this terrible genetic disease but in the process would also create genetically modified babies. I lobbied the UK Parliament …Read More